期刊
MOLECULES
卷 27, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/molecules27082523
关键词
COVID-19; main protease; Mpro; inhibitors
资金
- Universitat Jaume I [UJI-2021-71]
- SomUJIContraCovid (crowdfunding campaign)
- Ministerio de Universidades [FPU19/04913, FPU17/06209, FPU20/03516]
Since the outbreak of COVID-19, scientists have been searching for inhibitors of the main protease (Mpro) of the virus SARS-CoV-2 as potential new drugs. Through the design, synthesis, and testing of two different types of compounds, promising inhibitors have been identified as potential antiviral drugs.
Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported inhibitors of related proteases such as the main proteases of SARS-CoV and MERS-CoV were tested. A huge effort was then carried out by the scientific community to design, synthesize and test new small molecules acting as inactivators of SARS-CoV-2 Mpro. From the chemical structure view, these compounds can be classified into two main groups: one corresponds to modified peptides displaying an adequate sequence for high affinity and a reactive warhead; and the second is a diverse group including chemical compounds that do not have a peptide framework. Although a drug including a SARS-CoV-2 main protease inhibitor has already been commercialized, denoting the importance of this field, more compounds have been demonstrated to be promising potent inhibitors as potential antiviral drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据